Cell therapy in sarcoma: current landscape and future directions

Rákkutatás · Acute lymphoblastic leukemia

Cell therapy has emerged as a promising strategy, with the potential of durable clinical responses seen with genetically‑engineered T‑cell receptor T‑cell therapies (TCR‑T) such as those targeting the cancer‑testis antigen MAGE‑A4 in synovial sarcoma.

Sarcomas are rare malignancies of mesenchymal origin, characterized by significant biological and clinical heterogeneity. Many subtypes demonstrate limited sensitivity to standard systemic treatments, including immune checkpoint inhibitors. Cell therapy has emerged as a promising strategy, with the potential of durable clinical responses seen with genetically‑engineered T‑cell receptor T‑cell therapies (TCR‑T) such as those targeting the cancer‑testis antigen MAGE‑A4 in synovial sarcoma, leading to the US Food and Drug Administration approval of afamitresgene autoleucel in 2024. This constituted only the second approval of a cell therapy in a solid tumour following lifileucel in melanoma and demonstrated the potential of cell therapies in sarcomas. This review provides the current landscape and growing potential of cell therapies in sarcomas, including TCR‑T, chimeric antigen receptor‑T cells, tumor‑infiltrating lymphocytes, natural killer (NK) cells, and mesenchymal stromal cells. However, the broader application of these therapies is hindered by the lack of targetable sarcoma‑restricted immunogenic epitopes, spatiotemporal intratumoral heterogeneity, and a profoundly immunosuppressive tumour microenvironment that impedes effector‑cell trafficking, expansion and persistence. While cell therapies hold promise for integration into precision medicine approaches for sarcomas, their successful implementation will require careful evaluation of clinical feasibility, logistical considerations and cost‑effectiveness to optimise patient outcomes.

The statement highlights the pioneering role of cell‑based immunotherapies in treating sarcomas, a group of cancers that historically exhibit limited responsiveness to conventional systemic therapies.

Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.

Eredeti forrás

Kapcsolódó jelek